Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 2Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Glioblastoma 2Recurrence 1Lymphoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Cancers 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Carboplatin 9pembrolizumab 8Paclitaxel 8Cisplatin 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Gemcitabine 5fludarabine 4Specimen Handling 4Pemetrexed 4Nivolumab 4Cyclophosphamide 4trebananib 3osimertinib 3liposomal doxorubicin 3Radiotherapy 3Interleukin-2 3Fluorouracil 3Docetaxel 3DNA 3volociximab 2poly ICLC 2lenvatinib 2fludarabine phosphate 2Sorafenib 2Radiosurgery 2Midazolam 2Capecitabine 2Biopsy 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma × Crizotinib × Clear all
NCT01999972 2020-09-24

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Pfizer

Phase 1 Completed
50 enrolled 29 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡